News

Keya medical's plaque analysis and FFR-CT reports generated from a single CT scan.

The company now has multiple FDA-cleared algorithms for evaluating CCTA results.

Pi-Cardia ShortCut TAVR device

The FDA-cleared ShortCut leaflet modification device has been linked to positive real-world outcomes.

These "forward-thinking organizations" have all committed to participating in multiple data registries and quality improvement programs. Did your facility make the cut? 

Roderick Tung explains cardio-neuro ablation therapy for recurrent vasovagal syncope

The procedure is designed to help patients who experience frequent fainting episodes that impair their quality of life.

Medicare Advantage

"These high costs could pose barriers to care for such plans’ beneficiaries,” researchers wrote July 1 in the American Journal of Roentgenology

cybersecurity cyberattack hack hackers lock protection

The feds cautioned that exploitation of these vulnerabilities could allow attackers to write files, access unauthorized information, or crash client servers. 

Stravitz Sanyal Institute for Liver Disease and Metabolic Health at VCU

The Stravitz Sanyal Institute for Liver Disease and Metabolic Health at VCU seeks to develop new treatments that could help the millions of individuals impacted by these ailments. 

surgeon

With Election Day only four months away, healthcare is again emerging as a major source of idealistic campaign promises. Many of these are driven by widespread public angst. What sorts of changes can U.S. healthcare stakeholders realistically expect once the results are in? 

GE HealthCare

The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.” 

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Hexoskin Medical System

According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. 

Around the web

The company now has multiple FDA-cleared algorithms for evaluating CCTA results.

The FDA-cleared ShortCut leaflet modification device has been linked to positive real-world outcomes.

These "forward-thinking organizations" have all committed to participating in multiple data registries and quality improvement programs. Did your facility make the cut?